CTN Competitive Renewal FOA/RFA Out! |
SHARE ISSUE ON |
|
|
|
 CTN folks and other interested parties who have been waiting breathlessly for the CTN renewal RFA to come out can inhale (and then get to work!)—it has just been released!
The National Drug Abuse Treatment Clinical Trials Network (UG1 Clinical Trial Required)
This Funding Opportunity Announcement (FOA) invites applications from clinical investigators to participate in the National Drug Abuse Treatment Clinical Trials Network (CTN) and contribute to the network’s capacity to respond to urgent public health needs. NIDA intends to continue to develop and test interventions for addressing the wide spectrum of substance use problems via collaborative partnerships among NIDA, clinical research investigators, healthcare providers, and healthcare institutions.
Earliest submission date: October 15, 2019
Letter of intent due date: 30 days prior to application deadline
Application deadline: November 16, 2019 (5pm local time of applicant organization)
Find out more here and good luck to all applicants!
· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·
New in the CTN Dissemination Library
 Effects of access barriers and medication acceptability on buprenorphine-naloxone treatment utilization over 2 years: Results from a multisite randomized trial of adults with opioid use disorder. Evans EA, et al. Journal of Substance Abuse Treatment 2019;106:19-28.
Screening for substance use in rural primary care: A qualitative study of providers and patients. Saunders EC, et al. Journal of General Internal Medicine 2019 (in press).
|
CTN Trial Progress
 Randomizations for Active Studies as of the August 6* trial Progress Report. (*figures for September unavailable)
CTN-0067 - CHOICES Scale-Up. Enrolled 116
CTN-0068 - ADAPT-2 for Methamphetamine Use Disorder. Enrolled 403
CTN-0069 - OUD in the Emergency Department. Enrolled 543
CTN-0079 - ED-CONNECT
Enrolled 47
Total randomizations in active trials: 1109
|
· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·
News from the Nodes
Northeast Node
Northeast Node Investigators receive award for innovative work with opioid-exposed newborns
In June 2019, Northeast Node Core Investigators Steve Chapman, MD, and Daisy Goodman, DNP, alongside colleagues at Dartmouth-Hitchcock Medical Center (DHMC) Bonny Whalen, MD, Alison Holmes, MD, and Julia Frew, MD, received the Academic Pediatric Association’s Health Care Delivery award on behalf of the DHMC Center for Addiction Recovery in Pregnancy & Parenting (CARPP) for their tireless efforts to improve care and outcomes for opioid-exposed newborns and their moms.
CARPP is a multidisciplinary network of experienced clinicians and researchers at DHMC that focuses on supporting pregnant and parenting moms towards recovery from addiction and promoting healthy growth and development in their children.
The Center engages in research, patient education, and advocacy in the treatment of pregnant and parenting moms and children affected by substance use disorders. It also supports other providers who care for these families, with a particular focus on the impact of opioid use disorder.
Drs. Chapman and Goodman serve as Northeast Node Core Investigators and provide expertise in the fields of pediatrics and perinatal addiction treatment. The award was given during the 2019 Pediatric Academic Society’s annual meeting in Baltimore, MD.
You can find more information about CARPP on their website. · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·
Ohio Valley
 CTN-0080 Begins Pre-Initiation Activities
Study pre-initiation activities have begun for the CTN-0080 Medication Treatment for Opioid Use Disorder in Expectant Mothers (MOMs) study, led by Dr. Theresa Winhusen at the Ohio Valley Node.
The Wave 1 Investigator Meeting was held at the Cincinnati Westin July 29-31, 2019 and included the 6 Wave 1 sites and their nodes: Boston Medical Center/New England Node Consortium, CODA/Western States Node, Gateway/Florida Node Alliance, MUSC/Southern Consortium Node, PRC Magee Hospital/Appalachian Node, and UC Health/Ohio Valley Node.
Training for the Wave 2 sites is scheduled for September 16-18, 2019 at the Cincinnati Westin. |
Western States
 The University of California, San Francisco is currently accepting applications to its NIDA-funded two-year postdoctoral research training program in substance use treatment and services research. Positions are available beginning July 1, 2019. Scholars work with a preceptor to design and implement studies on treatment of substance use disorders (SUD), including nicotine, cannabis, opioids, and other substances. Scholars also select a specific area of focus for independent research. Current research interests of faculty include trials of efficacy and effectiveness of psychosocial and pharmacologic treatment of substance use disorders, including:
- Substance use disorders including cannabis, tobacco and opioids
- Innovative methodology, including internet-based studies
- Treatment of complex patients in health care settings
- Diagnostic techniques and research on treatment tailored for HIV-positive substance users with psychiatric and medical disorders
- Research on provision of services to substance-using populations
- Instrument development in substance use treatment
A variety of university-affiliated and community substance use treatment programs are available as research sites. These include inpatient- and outpatient-setting programs that treat a range of problems related to SUD treatment, including dependence on stimulants, cannabis, nicotine, alcohol, and opiates. The program encourages close research involvement with a preceptor, and involvement in selected classes, seminars, and grant preparation.
The training program is supported in part by the Western States Node of the NIDA Clinical Trials Network. Resources from other significant extramural funding and R01-level grants are also routinely available to scholars.
For more information, view/download/share our flyer.
· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·
ATTC Update
 From the ATTC/NIATx Service Improvement Blog
The Intersection of HIV and SUD: An Innovative Partnership to Educate and Support Two Critically Important Workforces by Beth Rutkowski, MPH, Pacific Southwest ATTC
The Role of Spirituality and Faith in the Treatment and Healing of SUDs by Dawn Tyus, LPC, MAC, NCC (Southeast ATTC) and Celene Craig, MPH, MS
|
· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·
Call for Papers: Translation Between Clinical & Preclinical Models of Individual Differences in Vulnerability in SUD
 This special issue of Experimental and Clinical Psychopharmacology will provide an overview of current translational research from both human and nonhuman animal researchers investigating individual difference factors in vulnerability to drug and alcohol use disorders.
The goal of the special issue is to highlight translational clinical and preclinical research and to catalyze future translational approaches in the field. The journal encourages submission of review articles and original research reports in these areas, including individual difference factors in environmental, trait, and/or genetic domains.
Editors also encourage research that is translational in nature and would be especially interested in paired-research articles from different laboratories that are investigating the same individual difference factors across clinical and preclinical models. If submitting paired articles, authors are also invited to submit a comment on that set of articles.
Nonhuman animal research that is translatable to the human conditions and human research that can be back translated to a nonhuman model are preferred. Papers addressing a variety of substances, including alcohol, marijuana, stimulants, and opiates, and their disorders, are welcome.
Submit review articles or primary research reports to Experimental and Clinical Psychopharmacology to be considered for inclusion in this special issue through the APA Online Submission Portal. The cover letter should indicate that the authors wish the manuscript to be considered for publication in the special issue on Advancing the Translation Between Clinical and Preclinical Models of Individual Differences in Vulnerability to Substance Use Disorders.
Deadline: Manuscripts must be submitted no later than October 1, 2019 to be considered for this issue. We strongly encourage individuals to contact the guest editors in advance with their ideas and a draft of the title and abstract. The special issue will be published in April 2020.
Questions or inquiries about the special issue can be directed to the Guest Editors of the issue, Melissa A. Cyders, PhD or Dustin J. Stairs, PhD, or the Editor, William W. Stoops, PhD.
· · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · · ·
Job Postings
 Director, Center on Alcoholism, Substance Abuse and Addictions, Univ. of New Mexico
UNM is launching a search for a Director for the Center on Alcoholism, Substance Abuse and Addiction (CASAA). THis is a tenured faculty position with full academic year salary support. CASAA was previously the home of the Southwest Node of the CTN (2002-2017) and is now part of the Southwest Node Core at UNM North Campus.
Read more here. . .
 CEO, Evergreen Treatment Services, Seattle
Evergreen Treatment Services (ETS) in Seattle is seeking a highly motivated professional to lead it into its next period of growth and community service. ETS has been an active participant in federally-funded research, working with the Pacific NW Node and others as part of the CTN, as well as in studies with other partners. Reporting to the Board of Directors, the CEO is responsible for the strategic direction of ETC.
Read more here. . . |
Also of Interest
 Funds for Research on Opioid Use and Suicide
The American Foundation for Suicide Prevention (AFSP) is interested in supporting research on the intersection of opioid use and suicide, and has grant funding opportunities at various levels that may be of interest to CTN researchers.
A Letter of Intent for Linked Standard Research Grants (research involving two or more institutions) should be submitted by September 15th. For all applications the next deadline is November 15, 2019.
Read more here. . .
September is Recovery Month
Every
September, SAMHSA sponsors Recovery Month to increase awareness and understanding of mental and substance use disorders and celebrate the people who recover.
The theme for 2019 is Join the Voices for Recovery: Together We Are Stronger.
For more about Recovery Month events, personal stories of recovery, and promotional materials, visit https://recoverymonth.gov/
|
   
|
